Iovance Biotherapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $99,313 | $71,430 | $86,771 | $67,455 |
Gross Profit | 55,718 | 28,932 | 43,660 | 28,978 |
EBITDA | -41,503 | -70,628 | -60,816 | -78,240 |
EBIT | -51,905 | -81,043 | -73,460 | -89,758 |
Net Income | -47,315 | -79,045 | -71,904 | -91,253 |
Net Change In Cash | 99,313 | 71,430 | 86,771 | 67,455 |
Free Cash Flow | -66,282 | -78,682 | -61,885 | -89,546 |
Cash | 110,768 | 196,508 | 163,078 | 158,134 |
Basic Shares | 450,189 | 418,511 | 406,966 | 364,037 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $263,502 | $164,070 | $1,189 | $238 |
Gross Profit | 90,318 | 40,075 | -9,566 | -21,135 |
EBITDA | -350,889 | -331,399 | -414,389 | -377,743 |
EBIT | -398,213 | -375,005 | -447,516 | -398,878 |
Net Income | -390,978 | -372,177 | -444,037 | -389,923 |
Net Change In Cash | 263,502 | 164,070 | 1,189 | 238 |
Free Cash Flow | -336,244 | -364,046 | -384,110 | -313,182 |
Cash | 163,078 | 115,694 | 114,888 | 231,731 |
Basic Shares | 357,345 | 289,877 | 235,131 | 159,259 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.11 |
2026-03-31 | -$0.19 |
2025-12-31 | -$0.18 |
2025-09-30 | -$0.25 |